Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DFYL50
|
|||
| Drug Name |
TJ004309
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 2 | [1] | |
| Company |
I-MAB Biopharma Shanghai, China
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Ecto-5'-nucleotidase (CD73) | Target Info | . | [1] |
| BioCyc | Purine nucleotides degradation | |||
| Urate biosynthesis/inosine 5'-phosphate degradation | ||||
| Adenosine nucleotides degradation | ||||
| KEGG Pathway | Purine metabolism | |||
| Pyrimidine metabolism | ||||
| Nicotinate and nicotinamide metabolism | ||||
| Metabolic pathways | ||||
| Panther Pathway | Purine metabolism | |||
| Pyrimidine Metabolism | ||||
| Pathway Interaction Database | HIF-1-alpha transcription factor network | |||
| Reactome | Purine catabolism | |||
| WikiPathways | Differentiation Pathway | |||
| miR-targeted genes in muscle cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| miR-targeted genes in epithelium - TarBase | ||||
| Metabolism of nucleotides | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05001347) A Phase 2 Clinical Study of TJ004309 in Combination With Atezolizumab (TECENTRIQ?) in Patients With Advanced or Metastatic Ovarian Cancers and Selected Advanced Solid Tumors. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.